We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Renalytix Plc | RENX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -2.00 | -9.52% | 19.00 | 08:37:03 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 21.00 | 19.00 | 21.00 | 19.00 | 21.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 14/11/2023 11:20 by idomeneo "74tom - 15 Mar 2022 - 12:57:11 - 1692 of 2344 Renalytix - AI Solutions Transforming The Management Of Kidney Disease - RENXIdomeneo, your posts remind me of a troll on a football forum pretending to support a team when they actually hate them. What you are saying is akin to going on a Spurs forum and posting that you think Harry Kane will leave on a free transfer or that he's going to retire at 28 to focus on other opportunities. It's complete nonsense to suggest RENX will run out of money, just like it was nonsense to say that raising $50m will double the share count or that shorters are here because they think RENX is like Theranos. Nobody who was invested here would be talking such rubbish, so please quit with the 'we' and go find something else to troll!" This was at £2.50 6 months after the 50 day and the 200 day had rolled over, the company had repeatedly claimed x was going to happen and it subsequently didn't. This guy went on to attack Paul Scott who has been a successful investor analysing several hundred companies a year for over 20 years and has unearthed many multi-baggers over that time. You get the same people who latch onto a stock and attack anybody else with a different view. As an investor you should be interested in looking at all the negatives of your investment, ideally this would be a place where that happens, but it never has. Where somebody would say " you are wrong for these reasons...". NB I didn't mention Theranos because it was a fraud and not relevant here, so he wrongly inferred that. |
Posted at 05/9/2023 05:46 by donald pond I can't help but feel we are getting close to the endgame here. Valuation is so low that if RENX can deliver a fraction of what the potential appears to be someone is going to buy them out soon. So the question is whether RENX can deliver, and whether the potential is what we think.I know they have FDA approval, but it doesn't feel as if there has been much take up since the CEO was talking about how revenues could jump from zero to hundreds of millions overnight, and IIRC that was in a podcast during covid lockdown. |
Posted at 01/9/2023 09:14 by mikemine1 No wonder the big boys are looking at RENX. I can't imagine how big this could be or how important this could be for the future of patient care. |
Posted at 21/8/2023 06:20 by mrmarmalade Nice to see this kept in the final report...BW MM |
Posted at 13/7/2023 12:11 by mikemine1 Correct me if I'm wrong but RENX has reached practically all it's milestones now except breakeven point. FDA was the last major hurdle even though that didn't stop the company gaining multiple insurance acceptances and recognition of the validity of it's product without it. It even has a link up with a huge sales outlet that should propel the revenue stream quicker than RENX could do themselves.It's all good to me and we only need to have a bit more patience to see what happens in the next 6 months. I also note the increased interest which has pushed the share price to the £1.40 mark from sub £1.00. Lots of reasons to be happy IMHO and lots of potential upside for the share price I reckon. |
Posted at 07/7/2023 06:36 by faz Normally stock options are granted to incentivise staff to achieve goals. Not with RENX. THey have just served out 2m options to the Board and the exercise price is the same as the current share price. And they vest in stages from three months time. An AIM stock of course. |
Posted at 01/7/2023 16:41 by mr roper Polx had zero sales strategy from memory.Renx at least have 50000 test candidates at Mt sinai alone and a sales force in the State. |
Posted at 30/6/2023 07:30 by nimbo1 Renx so far has been a diabolical investment - they have got timelines wrong (or perhaps right but lied to the market) on everything - including revenue projections, length of roll out and length to fda approval.It is possible this marks a turning point for the business and it can 10x from here. But it could only ever be a tiny punt for me as its more likely they continue over promising and hosing money. |
Posted at 30/6/2023 07:19 by 2theduke I think Renx moat of fda files for this type of test will be worth the current market cap. So that’s helpful alone . Gla |
Posted at 30/6/2023 07:12 by donald pond Interested to see what happens here. AGL is down 90% since it got FDA approval. But RENX has dropped 90% before that happened! The basic product has always seemed like a commercial win/win for all parties. If I was an insurer I'd be desperate to move customers onto annual tests as if it can delay dialysis the savings are huge. So let's see if approval causes a step change in adoption as that is what we need |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
